AFP and neoplasm: Decreased AFP after treatment portends higher ORR and DCR.<h4>Conclusion</h4>TACE combined Lenvatinib plus Camrelizumab regimen was safe and superior to TACE alone in improving PFS, OS, and tumor response rates for unresectable recurrent HCC patients.